These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node. Kitano M; Yamazaki C; Takumi A; Ikeno T; Hemmi H; Takahashi N; Shimizu K; Fraser SE; Hoshino K; Kaisho T; Okada T Proc Natl Acad Sci U S A; 2016 Jan; 113(4):1044-9. PubMed ID: 26755602 [TBL] [Abstract][Full Text] [Related]
8. Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration. He F; Wu Z; Liu C; Zhu Y; Zhou Y; Tian E; Rosin-Arbesfeld R; Yang D; Wang MW; Zhu D Signal Transduct Target Ther; 2024 May; 9(1):139. PubMed ID: 38811552 [TBL] [Abstract][Full Text] [Related]
9. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. Hartung E; Becker M; Bachem A; Reeg N; Jäkel A; Hutloff A; Weber H; Weise C; Giesecke C; Henn V; Gurka S; Anastassiadis K; Mages HW; Kroczek RA J Immunol; 2015 Feb; 194(3):1069-79. PubMed ID: 25520399 [TBL] [Abstract][Full Text] [Related]
10. Unexplored horizons of cDC1 in immunity and tolerance. Balan S; Radford KJ; Bhardwaj N Adv Immunol; 2020; 148():49-91. PubMed ID: 33190733 [TBL] [Abstract][Full Text] [Related]